Clinical Trial: Clinical Classification of MAFLD Based Liver Biopsy

U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06795646) titled 'Clinical Classification of MAFLD Based Liver Biopsy' on Jan. 20.

Brief Summary: Metabolic dysfunction-associated Fatty Liver Disease (MAFLD), also known as Non-Alcoholic Fatty Liver Disease (NAFLD), is the most common chronic progressive liver disease in China. It is closely related to the high incidence of cardiovascular-renal-metabolic syndrome and both liver and non-liver malignancies, posing a serious threat to public health. However, the diagnostic criteria for MAFLD are not unified globally, and the classification and staging still rely on liver biopsy for pathological assessment. The characteristics, mechanisms, and predictiv...